Latest Market Performance News

Tasman Resources has increased its investment in Eden Innovations through a $250,000 conditional share placement, raising its ownership to 13.95% and securing additional options. This move replaces further financial support and positions Tasman shareholders to benefit from Eden’s growth potential.

Epsilon Healthcare Limited is poised to return to ASX trading on 19 December 2025 after satisfying the exchange's conditions for reinstatement.

SportsHero Limited’s new HeroPlay mobile gaming platform is off to a strong start in Indonesia, attracting nearly 300 daily subscribers and generating early revenue that validates its market strategy.

Assetora Limited has raised $1.535 million through three placements, including a second investment from Creative Capital Management, to advance its alternative-asset platform.

Myer Holdings Limited reported steady FY25 financial results with $4.076 billion in sales and outlined ambitious growth strategies at its Annual General Meeting, alongside key director re-elections and executive incentives.

Ionic Rare Earths Limited secured shareholder approval on all resolutions at its 2025 Annual General Meeting, including director election, share consolidation, and capital raising measures.

TruScreen Group Limited reported a 17% decline in first half FY2026 product sales but affirmed full-year revenue guidance at NZ$2.8 million, supported by strategic expansions and a successful NZ$4 million capital raise.

Alicanto Minerals has appointed seasoned resources executive Jeffrey Sansom as CEO, signaling a strategic push to advance its Falun Copper-Gold Project and pursue new acquisitions. The leadership change aligns with the company’s ambitions to enhance shareholder value through disciplined growth.

Cauldron Energy Limited addresses a sharp share price rise, attributing it to strong uranium exploration results and market speculation linked to a sector takeover.

Black Cat Syndicate announces a leadership transition with James Bruce appointed as Managing Director from April 2026, succeeding founder Gareth Solly who will remain as a Non-Executive Director.

Ava Risk Group announces the upcoming retirement of CEO Mal Maginnis, with senior executive Neville Joyce appointed as Acting CEO. The company embarks on a global search for a permanent replacement amid strong recent growth.

AFT Pharmaceuticals reports a robust 33% revenue increase in the first half of FY26, driven by strong ANZ market performance and expanding international presence. The company advances its R&D pipeline and targets NZ$300 million revenue for FY27 amid strategic global expansion.